All News

The FDA approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The recent World Health Innovation Forum investigated the use of artificial intelligence in the medical field. Here are some takeaways.

The combination therapy dabrafenib plus trametinib approved for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer that cannot be removed by surgery or is metastatic.

Stuck at work for a 12 hour shift? Here are easy ways to fit in more activity during your shift.

Lonafarnib, a farnesyltransferase inhibitor, extended survival in patients with Hutchinson-Gilford progeria syndrome, or progeria.

PaxVax, an independent specialty vaccine company, is developing the prophylaxis.

Where does a pharmacist start after being released into the open job market?

Obstetricians and general practitioners most often field questions from women who have asthma, as this condition is more common than most other chronic conditions in young people.

Top news of the week from The American Journal of Pharmacy Benefits.

Allergic diseases such as asthma were associated with a 1.66-fold increased hazard of psychiatric disorders in Taiwan.

The approval includes the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Tisagenlecleucel (Kymriah, Novartis) is now approved for the treatment of diffuse large B-cell (DLBCL) lymphoma, as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Trametinib plus dabrafenib is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection.

The study found a calculable personal genetic risk score that was applicable to approximately 60,000 patients.

Although current guidelines recommend that HIV primary care intervals do not exceed 6 months, gaps in care up to 9 months do not worsen viral load for patients.

Upgrades to the insulin pen to improve disease management and prevent hypoglycemia due to overdoses are on the horizon.

Procter & Gamble (P&G) announced last month that it has agreed to acquire Merck KGaA’s consumer health unit for 3.4 billion euros or about $4.2 billion.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape.

BLU-667 is being investigated for the treatment of cancers caused by an alteration in the receptor tyrosine kinase.

Half of all HAE drug expenses were billed through the pharmacy benefit and half through the medical benefit.

HIV targets and disables a pathway involved in blocking viral activity and clearing infection.

Make sure that all individuals involved are exposed to the same process and treated equally, even though the infractions may differ.

The recent Escherichia coli (E.coli) outbreak linked to romaine lettuce is extremely virulent and has affected 22 states across the United States.

Poor study design and reporting in animal research compromises the ethical review of proposed human drug trials.